PE20151595A1 - Compuestos de pirazol-amida y sus usos farmaceuticos - Google Patents
Compuestos de pirazol-amida y sus usos farmaceuticosInfo
- Publication number
- PE20151595A1 PE20151595A1 PE2015001993A PE2015001993A PE20151595A1 PE 20151595 A1 PE20151595 A1 PE 20151595A1 PE 2015001993 A PE2015001993 A PE 2015001993A PE 2015001993 A PE2015001993 A PE 2015001993A PE 20151595 A1 PE20151595 A1 PE 20151595A1
- Authority
- PE
- Peru
- Prior art keywords
- pirazol
- amide compounds
- pharmaceutical uses
- diabetes
- hyperlactacidemia
- Prior art date
Links
- 102000053067 Pyruvate Dehydrogenase Acetyl-Transferring Kinase Human genes 0.000 abstract 2
- 101710159466 [Pyruvate dehydrogenase (acetyl-transferring)] kinase, mitochondrial Proteins 0.000 abstract 2
- 208000031229 Cardiomyopathies Diseases 0.000 abstract 1
- 208000002249 Diabetes Complications Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020660 Hyperlactacidaemia Diseases 0.000 abstract 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 208000031225 myocardial ischemia Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- -1 pyrazole amide Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C07C69/78—Benzoic acid esters
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invencion esta referida a compuestos derivados de pirazol-amida de Formula l, o sus sales farmaceuticamente aceptables, los cuales tienen actividad inhibidora de la piruvato deshidrogenasa cinasa (PDHK) y son empleados como agentes profilacticos o terapeuticos en el tratamiento de la diabetes, sindrome de resistencia a la insulina, sindrome metabolico. hiperglucemia, hiperlactacidemia, complicaciones diabeticas, insuficiencia cardiaca, cardiomiopatia, isquemia miocardica, infarto de miocardio, entre otras. Tambien se incluyen composiciones farmaceuticas que los contienen
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361791164P | 2013-03-15 | 2013-03-15 | |
JP2013053195 | 2013-03-15 | ||
JP2013127318 | 2013-06-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20151595A1 true PE20151595A1 (es) | 2015-11-24 |
Family
ID=51536938
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2015001993A PE20151595A1 (es) | 2013-03-15 | 2014-03-14 | Compuestos de pirazol-amida y sus usos farmaceuticos |
Country Status (31)
Country | Link |
---|---|
US (4) | US9040717B2 (es) |
EP (3) | EP3805205A1 (es) |
JP (6) | JP6208603B2 (es) |
KR (1) | KR102226096B1 (es) |
CN (1) | CN105051015B (es) |
AU (1) | AU2014230569B2 (es) |
BR (1) | BR112015022077A2 (es) |
CA (1) | CA2904985C (es) |
CL (1) | CL2015002608A1 (es) |
CY (1) | CY1120173T1 (es) |
DK (1) | DK2975028T3 (es) |
ES (1) | ES2663789T3 (es) |
HK (1) | HK1215808A1 (es) |
HR (1) | HRP20180635T1 (es) |
HU (1) | HUE036672T2 (es) |
IL (1) | IL241355B (es) |
LT (1) | LT2975028T (es) |
ME (1) | ME03090B (es) |
MX (1) | MX2015012743A (es) |
MY (1) | MY182884A (es) |
NO (1) | NO2975028T3 (es) |
PE (1) | PE20151595A1 (es) |
PH (1) | PH12015501993B1 (es) |
PL (1) | PL2975028T3 (es) |
PT (1) | PT2975028T (es) |
RS (1) | RS57188B1 (es) |
RU (1) | RU2664532C2 (es) |
SG (1) | SG11201507327TA (es) |
SI (1) | SI2975028T1 (es) |
TW (1) | TWI633885B (es) |
WO (1) | WO2014142290A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2897200C (en) | 2013-01-14 | 2021-07-06 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
BR122019024759B1 (pt) | 2013-01-15 | 2022-02-08 | Incyte Holdings Corporation | Compostos de tiazolacarboxamidas e piridinacarboxamida, composição compreendendo os mesmos, método de inibição da enzima pim1, pim2, ou pim3, e usos dos referidos compostos |
SG11201507327TA (en) * | 2013-03-15 | 2015-10-29 | Japan Tobacco Inc | Pyrazole-amide compound and medicinal uses therefor |
SG11201601259YA (en) | 2013-08-23 | 2016-03-30 | Incyte Corp | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors |
US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
US9920032B2 (en) | 2015-10-02 | 2018-03-20 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
BR112019001447A2 (pt) * | 2016-07-29 | 2019-05-07 | Japan Tobacco, Inc. | método de produção para composto pirazol-amida |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
MX2020008126A (es) * | 2018-02-01 | 2020-09-18 | Japan Tobacco Inc | Compuesto de amida heterociclica nitrogenada y su uso para fines medicos. |
JPWO2020054734A1 (ja) | 2018-09-11 | 2021-08-30 | 日本たばこ産業株式会社 | ピラゾール−アミド化合物を含有する慢性腎臓病の治療又は予防剤 |
US20220409548A1 (en) | 2019-03-04 | 2022-12-29 | Japan Tobacco Inc. | Amorphous solid dispersion of pyrazole-amide compound |
KR20220149688A (ko) * | 2020-03-04 | 2022-11-08 | 니뽄 다바코 산교 가부시키가이샤 | 축합 3환성 화합물 및 그의 의약 용도 |
AU2022337617A1 (en) * | 2021-09-01 | 2024-04-18 | Japan Tobacco Inc. | Nitrogen-containing tricyclic compound and pharmaceutical use thereof |
KR20240045387A (ko) * | 2022-09-28 | 2024-04-08 | (주)제이디바이오사이언스 | 신규한 플루오렌 유도체 및 이의 용도 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2827285B1 (fr) * | 2001-07-10 | 2003-12-05 | Rhodia Chimie Sa | Reactif et procede pour la perfluoroalcoylation |
TWI329111B (en) | 2002-05-24 | 2010-08-21 | X Ceptor Therapeutics Inc | Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
TW200418825A (en) | 2002-12-16 | 2004-10-01 | Hoffmann La Roche | Novel (R)-and (S) enantiomers of thiophene hydroxamic acid derivatives |
SI1620118T1 (sl) | 2003-04-08 | 2014-11-28 | Yeda Research And Development Co., Ltd. | Reverzibilna pegilirana zdravila |
RU2006107371A (ru) | 2004-02-20 | 2006-09-10 | Астеллас Фарма Инк. (Jp) | Флуореновые производные |
FR2885904B1 (fr) | 2005-05-19 | 2007-07-06 | Aventis Pharma Sa | Nouveaux derives du fluorene, compositions les contenant et utilisation |
RU2007147844A (ru) * | 2005-05-23 | 2009-06-27 | Джапан Тобакко Инк. (Jp) | Пиразольное соединение и содержащее его терапевтическое средство для лечения сахарного диабета |
US7767685B2 (en) * | 2006-06-29 | 2010-08-03 | King Pharmaceuticals Research And Development, Inc. | Adenosine A2B receptor antagonists |
FR2936173B1 (fr) * | 2008-09-22 | 2012-09-21 | Snecma | Procede pour la fabrication d'une piece en titane avec forgeage initial dans le domaine beta |
AR074797A1 (es) | 2008-10-10 | 2011-02-16 | Japan Tobacco Inc | Compuesto de fluoreno , composiciones farmaceuticas , inhibidores de pdhk y pdhk2 , metodos de tratamiento , usos de los mismos y kit comercial |
RU2011147232A (ru) * | 2009-04-22 | 2013-05-27 | Астеллас Фарма Инк. | Производное карбоновой кислоты |
TW201506015A (zh) * | 2013-03-15 | 2015-02-16 | Japan Tobacco Inc | 茀化合物的水合物以及其結晶 |
SG11201507327TA (en) * | 2013-03-15 | 2015-10-29 | Japan Tobacco Inc | Pyrazole-amide compound and medicinal uses therefor |
JP2015028010A (ja) | 2013-07-01 | 2015-02-12 | 日本たばこ産業株式会社 | フルオレン−アミド化合物およびその医薬用途 |
TW201536749A (zh) | 2013-07-01 | 2015-10-01 | Japan Tobacco Inc | 吡唑-醇化合物及其醫藥用途 |
-
2014
- 2014-03-14 SG SG11201507327TA patent/SG11201507327TA/en unknown
- 2014-03-14 MX MX2015012743A patent/MX2015012743A/es active IP Right Grant
- 2014-03-14 PL PL14763385T patent/PL2975028T3/pl unknown
- 2014-03-14 DK DK14763385.3T patent/DK2975028T3/en active
- 2014-03-14 RS RS20180492A patent/RS57188B1/sr unknown
- 2014-03-14 HU HUE14763385A patent/HUE036672T2/hu unknown
- 2014-03-14 PT PT147633853T patent/PT2975028T/pt unknown
- 2014-03-14 EP EP20204677.7A patent/EP3805205A1/en not_active Withdrawn
- 2014-03-14 NO NO14763385A patent/NO2975028T3/no unknown
- 2014-03-14 KR KR1020157028869A patent/KR102226096B1/ko active IP Right Grant
- 2014-03-14 EP EP18156002.0A patent/EP3348545A1/en not_active Withdrawn
- 2014-03-14 SI SI201430703T patent/SI2975028T1/en unknown
- 2014-03-14 RU RU2015144182A patent/RU2664532C2/ru active
- 2014-03-14 CA CA2904985A patent/CA2904985C/en active Active
- 2014-03-14 WO PCT/JP2014/056825 patent/WO2014142290A1/ja active Application Filing
- 2014-03-14 LT LTEP14763385.3T patent/LT2975028T/lt unknown
- 2014-03-14 BR BR112015022077A patent/BR112015022077A2/pt not_active Application Discontinuation
- 2014-03-14 PE PE2015001993A patent/PE20151595A1/es active IP Right Grant
- 2014-03-14 EP EP14763385.3A patent/EP2975028B1/en active Active
- 2014-03-14 ES ES14763385.3T patent/ES2663789T3/es active Active
- 2014-03-14 US US14/210,746 patent/US9040717B2/en active Active
- 2014-03-14 CN CN201480016173.0A patent/CN105051015B/zh active Active
- 2014-03-14 JP JP2014050964A patent/JP6208603B2/ja active Active
- 2014-03-14 MY MYPI2015703124A patent/MY182884A/en unknown
- 2014-03-14 TW TW103109400A patent/TWI633885B/zh not_active IP Right Cessation
- 2014-03-14 AU AU2014230569A patent/AU2014230569B2/en not_active Ceased
-
2015
- 2015-04-22 US US14/692,846 patent/US20160074364A1/en not_active Abandoned
- 2015-09-08 PH PH12015501993A patent/PH12015501993B1/en unknown
- 2015-09-09 IL IL241355A patent/IL241355B/en active IP Right Grant
- 2015-09-11 CL CL2015002608A patent/CL2015002608A1/es unknown
-
2016
- 2016-04-01 HK HK16103742.7A patent/HK1215808A1/zh not_active IP Right Cessation
-
2017
- 2017-09-07 JP JP2017171644A patent/JP2018021061A/ja not_active Ceased
- 2017-10-06 US US15/726,569 patent/US20180256547A1/en not_active Abandoned
-
2018
- 2018-03-14 ME MEP-2018-110A patent/ME03090B/me unknown
- 2018-04-20 CY CY20181100419T patent/CY1120173T1/el unknown
- 2018-04-23 HR HRP20180635TT patent/HRP20180635T1/hr unknown
- 2018-07-05 JP JP2018128272A patent/JP2018188449A/ja not_active Ceased
-
2019
- 2019-06-06 JP JP2019105806A patent/JP2019194197A/ja not_active Ceased
- 2019-07-02 US US16/459,959 patent/US20200163937A1/en not_active Abandoned
-
2020
- 2020-08-05 JP JP2020133190A patent/JP2020189855A/ja not_active Ceased
-
2021
- 2021-09-22 JP JP2021153931A patent/JP2022000453A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20151595A1 (es) | Compuestos de pirazol-amida y sus usos farmaceuticos | |
NI201600018A (es) | Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b. | |
CU20150014A7 (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
PH12017502001A1 (en) | Amido-substituted cyclohexane derivatives | |
ECSP15014941A (es) | Compuestos antivíricos para el vsr | |
ECSP088747A (es) | Pirazoles como inhibidores de la 11-beta-hsd1 | |
GT201300215A (es) | Inhibidores de glucosilceramida sintasa | |
DOP2015000241A (es) | Compuestos de biaril-amida como inhibidores de cinasa | |
NI201300074A (es) | Novedosos derivados de azabencimidazol cíclico útiles como agentes antidiabéticos. | |
CR20180232A (es) | Macrociclos peptídicos contra acinetobacter baumannii | |
CL2011001082A1 (es) | Compuestos derivados de amino-tetrahidropiranos sustituidos con heterociclos, composicion farmaceutica; y uso en el tratamiento de una afeccion seleccionada de resistencia a la insulina, hiperglicemia y diabetes de tipo 2. | |
MX2015008628A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
ECSP13013068A (es) | Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2 | |
ECSP13013024A (es) | 1,3-oxazinas como inhibidores de bace1 y/o bace2 | |
UY31616A1 (es) | Derivados de urea de tetrahidroquinoxalina, su preparación y su aplicación en terapéutica | |
CU20130036A7 (es) | Triazina-oxidazoles | |
CO6670520A2 (es) | Lactmas sustituidas con piperidinio como moduladores de gpr119 | |
CR20170092A (es) | Compuestos y composiciones como inhibidores de quinasa raf | |
UY36875A (es) | Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades | |
DOP2015000170A (es) | Compuestos químicos | |
UY31968A (es) | Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos | |
PE20171243A1 (es) | Composicion de liberacion modificada de orlistat y acarbosa para el tratamiento de la obesidad y trastornos metabolicos relacionados | |
CL2021001388A1 (es) | Compuestos útiles en la terapia para el vih | |
CL2016000026A1 (es) | Nuevos derivados de azabencimidazol | |
UY36416A (es) | 1-[2-(aminometil)bencil]-2-tioxo-1,2,3,5-tetrahidro-4h-pirrolo[3,2-d]pirimidin-4-onas como inhibidores de la mieloperoxidasa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |